Modified stem cells for severe graft-versus-host disease
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 4 and 70 years old.
- You have acute graft-versus-host disease that is not responding to steroid treatment.
- Your overall health is good enough to be up and about (ECOG score 0 to 2).
- You have not received stem cell treatments before for this condition.
- You do not have severe liver, kidney, heart, or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
This study tests an experimental cell therapy called VUM02 for people who have graft-versus-host disease (GvHD) after a stem cell transplant that hasn't improved with standard steroid treatment. The goal is to see if this new treatment can help control GvHD symptoms and improve outcomes.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
Hear when a new Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.